Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. (Q51924516)

17 April 2018

title

Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. (English)

1 reference

17 April 2018

0 references

1 reference

17 April 2018

Robert Perneczky

1 reference

17 April 2018

Holger Jahn

1 reference

17 April 2018

Johannes Kornhuber

1 reference

17 April 2018

Harald Hampel

Harald Hampel

1 reference

17 April 2018

Frank Jessen

1 reference

17 April 2018

Olive Melissa Minor Peters

Oliver Peters

1 reference

17 April 2018

Juan Manuel Maler

Juan Manuel Maler

1 reference

17 April 2018

Piotr Lewczuk

Piotr Lewczuk

1 reference

17 April 2018

Hermann Esselmann

Hermann Esselmann

1 reference

17 April 2018

Mirko Bibl

Mirko Bibl

1 reference

17 April 2018

Lutz Frölich

Lutz Frölich

1 reference

17 April 2018

Michael Hull

Michael Hüll

1 reference

17 April 2018

Christian Luckhaus

Christian Luckhaus

1 reference

17 April 2018

Magdalena Fiszer

Magdalena Fiszer

1 reference

17 April 2018

Ralf Bruckmoser

Ralf Bruckmoser

1 reference

17 April 2018

author name string

Holger Kessler

1 reference

17 April 2018

Johannes Schröder

1 reference

17 April 2018

Rüdiger Zimmermann

1 reference

17 April 2018

language of work or name

English

0 references

publication date

24 January 2007

1 reference

17 April 2018

Journal of Neurochemistry

published in

1 reference

17 April 2018

volume

101

1 reference

17 April 2018

issue

1 reference

17 April 2018

page(s)

1053-1059

1 reference

17 April 2018

Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 --> Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

The Bayer Activities of Daily Living Scale (B-ADL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Genotype and phenotype in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Expression of the Alzheimer protease BACE1 is suppressed via its 5'-untranslated region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Electrophoretic separation of amyloid beta peptides in plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Evaluation and use of diagnostic tests in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

A new multiphasic buffer system for sodium dodecyl sulfate-polyacrylamide gel electrophoresis of proteins and peptides with molecular masses 100,000-1000, and their detection with picomolar sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Improved electrophoretic separation and immunoblotting of beta-amyloid (A beta) peptides 1-40, 1-42, and 1-43.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04404.X

10.1111/J.1471-4159.2006.04404.X

21 January 2018

Identifiers

DOI

1 reference

17 April 2018

1 reference

17 April 2018